Navacaprant
Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140), is an opioid antagonist medication which is under development for the treatment of depression.[1][2][3] It is specifically a selective κ-opioid receptor antagonist and is under development for major depressive disorder.[1][2][3] As of December 2023, navacaprant is in phase 3 clinical trials for this indication.[4]
See also
- κ-Opioid receptor § Antagonists
- List of investigational antidepressants
References
- ^ a b "BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders". BlackThorn Therapeutics. Archived from the original on 2020-01-25. Retrieved 2020-01-25.
- ^ a b "BTRX 335140 - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.
- ^ PMID 30707578.
- ^ Neumora Therapeutics, Inc. (2024-02-20). A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (Report). clinicaltrials.gov.
External links